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Abstract
 Background: This study was designed to evaluate prevalence of the metabolic syndrome among cancer 
survivors compared to non-cancer controls from a population-based sample and to identify associated risk 
factors. Materials and Methods: Data from the fourth Korean National Health and Nutrition Examination 
Survey were analyzed to compare the prevalence of metabolic syndrome, as defined by 2009 consensus 
criteria. Associated factors with were identified using multiple logistic regression analysis among cancer 
survivors.  Results: The prevalence of the metabolic syndrome in cancer survivors (n = 335) was similar 
to that in the non-cancer population (n = 10,671). However, gastric cancer survivors showed lower risk of 
metabolic syndrome than non-cancer controls (adjusted odds ratio [aOR] 0.42, 95% confidence interval [CI] 
0.20-0.86). Age of more than 60 years (aOR 4.83, 95% CI 1.94−12.03), BMI between 23 and 25 (aOR 6.71, 
95% CI 2.90−15.6), BMI more than 25 (aOR 12.23, 95% CI 5.20−28.77) were significantly associated with 
the metabolic syndrome in cancer survivors.  Conclusions: Cancer survivors are unlikely to have a higher 
risk of the metabolic syndrome than non-cancer controls in Korea. This finding may be due to a relatively 
high proportion of gastric cancer survivors in Korea than in Western countries. The risk for metabolic 
syndrome among cancer survivors would appear to vary according to oncological and non-oncological 
factors. 
Key words : Metabolic syndrome - cancer survivors - prevalence - risk factors - Korea
1Department of Obstetrics and Gynecology, 2Department of Family Medicine, Seoul National University College of Medicine, 
Seoul, 3Department of Family Medicine, Dongnam Institute of Radiological & Medical Science, Busan, Korea *For corre-
spondence: sangmin.park.snuh@gmail.com  
Asian Pacific J Cancer Prev, 14, 1773-1780
Introduction
 The number of cancer survivors has increased 
rapidly due to increased incidence of overall cancer 
and the improved survival of cancer patients (Boyle 
and Levin, 2008; Jung et al., 2011). The proportion 
of cancer survivors is up to 3.7% in the United States 
and 1% in Korea (National Cancer Information Center, 
2011; National Cancer Institute, 2012). Cancer survivors 
have more comorbidities than the general population 
(Shin et al., 2008). Furthermore, cancer survivors had 
an increased risk of developing cardiovascular disease 
as results of late effects of several cancer therapies 
such as platinum compounds, angiogenesis inhibitors, 
and radiation treatment (Redig and Munshi, 2010). 
Thus, evaluation and management of accompanied 
comorbidities as well as survival itself have become 
important issues in cancer survivors. Cardiovascular 
disease is the most important cause of non-cancer death 
in cancer-survivors that affect life expectancy and quality 
of life (Brown et al., 1993; Shin et al., 2010a). It is now 
well recognized that metabolic syndrome is associated 
with increased risk of cardiovascular events and mortality 
(Gami et al., 2007). Therefore, risk for cardiovascular 
disease could be assessed by measuring metabolic 
syndrome components (Cabre et al., 2008).
   Previous studies showed inconsistent results whether 
the risk of metabolic syndrome is more increased in 
cancer survivors than general populations. In long-term 
survivors of childhood cancer, the trends for increased 
risk of metabolic syndrome were observed in several 
studies (Talvensaari et al., 1996; Follin et al., 2006; 
Gurney et al., 2006; Oeffinger et al., 2006; Annaloro et 
al., 2008). As for survivors of adult-onset solid tumors, 
most studies were limited to some specific cancer types 
such as testicular cancer and prostate cancer (Nuver et 
al., 2005; Braga-Basaria et al., 2006; Haugnes et al., 
2007). Several studies from adult-onset solid tumors have 
demonstrated that the results were inconsistent according 
to types of cancer and treatment modalities (Nuver et 
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al., 2005; Haugnes et al., 2007; Liavaag et al., 2009; 
Ulaganathan et al., 2012). A recent meta-analysis showed 
no significant association with metabolic syndrome for 
non-hematologic malignancies (Jung et al., 2012).
 Few studies about the association between metabolic 
syndrome and cancer survivors have been performed 
in Asia, where the leading causes of cancer differ from 
Western countries. In Korea, the top five prevalent cancer 
types are the stomach, colorectum, liver, prostate, and 
lung among male cancer survivors, whereas thyroid, 
breast, stomach, colorectum, and cervix uteri are the 
top five among female (Jung et al., 2011). The risk of 
metabolic syndrome in Korean cancer survivors could 
be affected from the differences in race and in leading 
cancer types. Moreover, socio-demographic, behavioral, 
and cultural factors of Korean cancer survivors are 
different from western countries, and could affect the 
long-term consequences. The objectives are to evaluate 
the prevalence of metabolic syndrome and identify risk 
factors, including oncological and non-oncological 
factors, among Korean cancer survivors. 
Materials and Methods
Overview of survey and study population
  The fourth Korean National Health and Nutrition 
Examination Survey 2007-2009 (KNHANES IV) was 
a nationally representative survey conducted by the 
Division of Chronic Disease Surveillance under the 
Korea Centers for Disease Control and Prevention on an 
annual basis since 1998 to accurately determine national 
health and nutrition levels and for the purpose of gaining 
basic data (Korea Centers for Disease Control and 
Prevention, 2010). The survey is composed of 3 parts: (1) 
health interview survey, (2) health examination survey, 
and (3) nutritional survey. A face to face interview at 
participants’ home by trained interviewers was applied to 
gather health interview survey. The standardized health 
examination survey was conducted in specially equipped 
mobile examination centers.
 A stratified multistage clustered probability sampling 
was used to choose a representative sample of the non-
institutional civilian population (see Figure 1). The 
sampling frame of participants was derived from the 2005 
Population Census. Stratification was conducted based 
on the 13 areas of Korea (seven metropolitan cities and 
six provinces), administrative unit (dong or eup-myeon; 
Korean units), and the dwelling type (apartment house 
or others). From a total of 3,573 administrative units, 
500 primary sampling units (PSUs) were randomly 
allocated as follows: 100 in 2007, 200 in 2008 and 
200 in 2009, respectively. Twenty households per PSU 
were randomly derived from those primary sampling 
units with age and sex stratification. A total of 4594, 
9744, and 10533 participated in the health interview 
survey or health examination surveys of 2007, 2008, 
and 2009, respectively, with response rates of 71.2, 
77.8, and 82.8%. Out of 24,871 subjects, blood tests 
were performed on 23,631 (4246 in 2007, 9307 in 2008, 
and 10078 in 2009) individuals aged ≥10 years. After 
excluding 12,003 participants aged less than 40 years, 
11,628 subjects were used for the current study. Subjects 
with any missing data for the metabolic syndrome 
component of the survey were excluded (n=622). The 
subjects included in our study were 11,006 persons who 
were aged ≥ 40 years and completed tests for metabolic 
syndrome component. Cancer survivors were classified 
if they reported having ever been told by a doctor that 
they had cancer or a malignancy of any kind. The cancer 
survivors were 335 persons as the final population. 
Institutional Review Board approval was waived due to 
using open data sets to public. 
Associated factors and definition of metabolic syndrome
  We collected information about various factors that 
could be associated with risk of metabolic syndrome. 
We assessed variables related to socio-demographic 
factors, behavioral factors, psychological factors, and 
oncological factors. The socio-demographic variables 
were sex, current age (<60 years and ≥60 years), 
education level (less than elementary school, middle/
high school, and more than college), monthly household 
income (<573 $, 573-1,332$ and ≥1,332$) and residential 
area (urban or rural). Household monthly income was 
divided into tertiles, and income per adult equivalent was 
calculated using the formula household income/square 
root of the number of persons in the household.
  Behavioral risk factors included body mass index 
(BMI), current smoking status (no or yes), heavy alcohol 
consumption (no or yes), and the level of physical activity 
(inadequate or adequate). BMI was obtained from each 
subjects and categorized as follows: <23, 23−25, and ≥25 
(WHO, 2000). Heavy alcohol consumption was defined 
as consumption of 5 or more drinks on a single occasion, 
or drinking almost every day. Subjects were asked 
about their average frequency and amount of alcoholic 
beverage intake during the year before the interview. 
Heavy alcohol consumption was defined by self-reported 
Subjects who participated in KNHANES IV (n = 24,871) 
Subjects who participated in blood test (n = 23,631)  
Subjects aged more than 40 years (n = 11,628) 
 Excluded individuals who did not participate in blood test (n = 1,240)   
Excluded subjects aged less than 40 years (n = 12,003)  
Subjects who completed tests for metabolic syndrome components (n = 11,006) 
Excluded subjects who had missing data for metabolic syndrome  
components (n = 622) 
Figure 1.  Flow Diagram Showing Selection of the 
Study Population 
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more than 5 drinks on a single occasion, or daily drinking 
of more than 1 drink per day (Amparo et al., 2011). We 
defined adequate physical activity as doing 30 minutes 
of moderate-intensity physical activity on 5 or more days 
of the week or 20 minutes of vigorous-intensity physical 
activity on 3 or more days of the week as recommended 
by the American College of Sports Medicine and the 
American Heart Association (Haskell et al., 2007).
  Psychological factors were self-reported depression 
(no or yes) and suicidal ideation within 1 year (no or yes). 
Self-reported depression was determined if participants 
reported having ever been diagnosed as depression by a 
doctor. Oncological factors were cancer types (gastric, 
breast, cervix uteri, and other cancer type) and duration 
since diagnosis (<5, 5−10, ≥10 years). Cancer survivors 
were also asked about the site and the age of diagnosis. 
In our study, we classified cancer types as gastric, colon, 
breast, cervix uteri, and other cancer. The cancer type 
which included less than 20 subjects was classified as 
other cancer. Therefore, several common cancers such 
as liver, lung, prostate, thyroid, esophagus, pancreas, and 
ovary were classified as other cancer type due to small 
number in this survey.
  Metabolic syndrome were defined as a combination 
of clinical disorders that includes the presence of 
three or more indicators: 1) abdominal obesity (waist 
circumference >90 cm in males or 80 cm in females), 
standard values modified by Asian standards; 2) high 
triglyceride level (≥150mg/dL); 3) low level of high 
density lipoprotein (<40 mg/dL); 4) high blood pressure 
(≥130/85 mmHg); 5) high fasting plasma glucose 
(≥100mg/dL); 6) current medication for treatment of any 
of the above conditions such as statins, anti-hypertensive 
drugs, anti-diabetic medications, according to the 2009 
consensus criteria and the waist circumference criteria 
of the Regional Office for the Western Pacific Region of 
World Health Organization (Alberti et al., 2009).
Statistical Analysis
  The calculated sampling weights were available 
from the KNHANES dataset to consider the sampling 
and response rates. This was particularly important for 
survey data because the sampling probabilities could 
be different among sampling clusters (Lehtonen and 
Pahkinen, 2004). Thus, we used the sampling weights 
that the KNHANES provided for all of the data analyses 
in this study. All estimates in the analysis were properly 
weighted to represent the general population. Descriptive 
statistical methods were used to demonstrate the basic 
characteristics of the study population; estimated 
proportion and standard errors were reported for each 
variable. The prevalence of each component of metabolic 
syndrome was measured according to cancer survivors 
and non-cancer controls. We evaluated the adjusted 
proportion of metabolic syndrome according to each 
cancer type (gastric, colon, breast, cervix uteri) and 
non-cancer controls. Multi-dimensional approach to 
identify factors associated with metabolic syndrome 
Table 1. Baseline Characteristics   
 
Variables Non−cancer           Cancer       P-value 
                                 controls       survivors    
  (N=10671)     (N=335)
                        
Socio−demographic factors   
  Sex   
    Male 48.9(0.6) 34.9(3.4) 
    Female 51.1(0.6) 65.1(3.4) <0.001
  Age   
    40−59 68.6(0.5) 48.8(3.5) 
    ≥60  31.4(0.5) 51.2(3.5) <0.001
  Education level   
     ≤Elementary 34.2(0.6) 43.1(3.4) 
     Middle/high 46.6(0.6) 42.1(3.6) 
     ≥College 19.2(0.6) 14.8(2.8) 0.037
  Monthly income ($)   
     <573 26.1(0.5) 28.5(2.9) 
     573−1,332 36.2(0.6) 35.0(3.4) 
     ≥1,332 34.1(0.6) 31.3(3.4) 0.483
  Residential area   
     Urban 45.8(0.6) 51.8(3.5) 
     Rural 54.2(0.6) 48.2(3.5) 0.092
Behavioral factors   
  BMI   
     <23 36.9(0.6) 45.7(3.5) 
     ≥23 & <25 26.5(0.5) 23.9(3.1) 
     ≥25  36.6(0.6) 30.5(3.4) 0.042
  Smoking   
     Non or past smoker 77.3(0.5) 90.3(2.5) 
     Current smoker 22.7(0.5) 9.7(2.5) <0.001
  Alcohol   
     Non 71.1(0.6) 91.9(2.4) 
     Heavy drinkinga 28.9(0.6) 8.1(2.4) <0.001
  Physical activity   
     Inadequate 73.7(0.5) 70.3(3.3) 
     Adequateb 26.3(0.5) 29.7(3.3) 0.283
Psychological factors   
  Self−reported depression   
     No  94.9(0.2) 94.2(1.4) 
     Yes  5.1(0;2) 5.8(1.4) 0.614
  Suicidal idea within 1 year   
     No   81.4(0.5) 78.1(2.8) 
     Yes  18.3(0.5) 21.7(2.8) 0.306
Oncological factors   
  Type   
     Gastric  21.5 (2.7) 
     Colon  9.8(2.4) 
     Breast  16.1(2.7) 
     Cervix uteri  21.2(3.0) 
     Other  31.4(3.2) 
  Duration since diagnosis   
     <5    50.0(3.5) 
     ≥5 & <10  21.2(2.8) 
     ≥10   28.9(3.3) 
SE, standard error; a Heavy drinking defined as self-reported 
more than 5 drinks on a single occasion, or daily drinking of 
more than 1 drink per day; bAdequate physical activity defined 
as doing 30 minutes of moderate-intensity physical activity 
on 5 or more days of the week or 20 minutes of vigorous−
intensity physical activity on 3 or more days of the week  
among cancer survivors was used. First, odds ratios 
(OR) for metabolic syndrome were calculated by 
univariate analysis. Then, multiple logistic regression 
analysis was performed by adjusting socio-demographic 
factors, psychological factors, behavioral factors, and 
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oncological factors. Adjusted odds ratio (aOR) and 95% 
confidence intervals (CI) were calculated to show the 
strength of each association. P-values less than 0.05 were 
considered significant, and all statistical tests were two-
sided. All statistical tests were performed using STATA 
11.0 (Stata Corp., College Station, Texas, USA). 
Results
Baseline characteristics
A positive cancer history was reported by 
approximately 3% of the study population. The baseline 
characteristics of study participants are summarized in 
Table 1. Cancer survivors were older than non-cancer 
controls (≥ 60 years: 51.2% vs. 31.4%, respectively), 
and more likely to be female (65.1% vs. 51.1%, 
respectively). Cancer survivors were less likely to be 
obese than the general population (BMI ≥25: 30.5% 
vs. 36.6%, respectively). High risk behaviors such as 
smoking and heavy alcohol drinking were less likely to be 
observed in cancer survivors than in non-cancer controls 
(current smoking: 9.7% vs. 22.7% and heavy alcohol 
consumption 8.1% vs. 28.9%, respectively). Among 
cancer survivors, gastric cancer was the most common 
cancer (23%), followed by cervix uteri (21.2%), breast 
cancer (16.3%), and colon cancer (9.8%).  Approximately 
50% survived more than 5 years after diagnosis. 
Metabolic syndrome components among cancer 
survivors and non-cancer controls
The crude proportions of metabolic syndrome were 
28.5% in cancer survivors and 33.5% in the general 
population, respectively. Table 2 showed the prevalence 
of each metabolic syndrome component according to 
cancer status. The prevalence of elevated blood pressure, 
systolic blood pressure ≥130 mmHg or diastolic blood 
pressure ≥85 mmHg, was 30.9% in cancer survivors and 
38.7% in non-cancer controls (P = 0.02). In addition, the 
crude proportion of elevated triglycerides was 23.1% in 
cancer survivors and 35.3% in the general populations (P 
< 0.001). The risk for metabolic syndrome among cancer 
survivors was lower than non-cancer controls, but this 
association was not statistically significant (aOR 0.80, 
95% CI 0.56−1.14). Gastric cancer survivors showed 
decreased aOR for metabolic syndrome than non-cancer 
controls (aOR 0.42, 95% CI 0.20−0.86). When we 
evaluated cancer survivors by excluding gastric cancer 
survivors, a similar risk for metabolic syndrome was 
observed compared to non-cancer controls (aOR 0.96, 
95% CI 0.64−1.45). Colon cancer and breast cancer 
survivors had higher risk for metabolic syndrome than 
non-cancer controls, but none of them were statistically 
significant. 
We separated our sample into two subgroups 
according to age group (40−59 years and ≥60 years) 
and performed a subgroup analysis. We did not find a 
significant difference in the risk of metabolic syndrome 
between cancer survivors and non-cancer controls 
across different age groups. In participants who aged 
40−59 years, cancer survivors were not at higher risk for 
metabolic syndrome compared to non-cancer controls 
(aOR 0.66, 95% CI 0.34−1.28). Similarly in the older 
age group (≥60 years), cancer survivors did not have 
significantly different risk for metabolic syndrome 
Table 2. Metabolic Syndrome Components among Cancer Survivors and Controls (N = 11,106)   
    
Components Non−cancer   Cancer Gastric cancer Colon cancer Breast Cancer Uterine cervix    Other Cancer
                                                     controls            Survivors                 survivors                survivors                 survivors           Cancer Survivors            survivors
 (N = 10,671) (N = 335) (N = 82) (N = 30) (N = 48) (N = 65) (N = 110)
Abdominal Obesity        
   Estimated proportion % (SE) 41.7 (0.6) 41.9 (3.5) 19.8 (6.2) 46.7 (13.1) 60.1 (8.7) 43.4 (7.8) 45.1 (6.0)
   Crude OR (95% CI) 1 1.01 (0.76−1.34) 0.35 (0.16−0.75) 1.22 (0.43−3.45) 2.10 (1.03−4.30) 1.07 (0.57−2.00) 1.15 (0.72−1.85)
   Adjusted ORb (95% CI) 1 1.00 (0.61−1.64) 0.44 (0.23−0.85) 3.39 (0.95−12.12) 1.06 (0.47−2.38) 0.60 (0.16−2.28) 1.26 (0.57−2.80)
High triglyceride        
   Estimated proportion % (SE) 35.3 (0.6) 23.1 (3.1) 7.7 (2.6) 23.0 (9.1) 24.5 (9.7) 28.4 (7.6) 29.4 (5.3)
   Crude OR (95% CI) 1 0.55 (0.39−0.78) 0.15 (0.07−0.32) 0.55 (0.20−1.49) 0.60 (0.21−1.66) 0.73 (0.35−1.52) 0.76 (0.46−1.27)
   Adjusted ORb (95% CI) 1 0.67 (0.46−0.97) 0.18 (0.09−0.36) 0.43 (0.13−1.41) 0.77 (0.26−2.25) 1.13 (0.47−2.75) 0.89 (0.54−1.48)
Low HDL cholesterol        
   Estimated proportion % (SE) 43.7 (0.6) 48.2 (3.5) 36.8 (6.7) 48.4 (13.0) 73.2 (7.1) 47.1 (8.0) 43.8 (6.0)
   Crude OR (95% CI) 1 1.20 (0.90−1.59) 0.75 (0.42−1.32) 1.21 (0.44−3.36) 3.51 (1.72−7.18) 1.15 (0.61−2.16)  1.01 (0.62−1.62)
   Adjusted ORb (95% CI) 1 1.05 (0.78−1.41) 0.84 (0.48−1.44) 1.39 (0.46−4.18) 2.28 (1.17−4.46) 0.82 (0.40−1.67) 0.91 (0.54−1.54)
High blood pressure        
   Estimated proportion % (SE) 38.7 30.9 (3.2) 31.5 (5.6) 39.1 (13.6) 44.9 (9.1) 28.2 (6.6) 22.6 (4.8)
   Crude OR (95% CI) 1 0.71 (0.53−0.95) 0.73 (0.44−1.22) 1.02 (0.33−3.14) 1.29 (0.62−2.67) 0.62 (0.33−1.18) 0.46 (0.27−0.79)
   Adjusted ORb (95% CI) 1 0.68 (0.50−0.92) 0.62 (0.37−1.05) 0.70 (0.25−2.01) 1.61 (0.78−3.34) 0.86 (0.46−1.60) 0.38 (0.22−0.67)
Impaired glucose tolerance        
   Estimated proportion % (SE) 34.4 (0.6) 31.1 (3.2) 24.9 (5.5) 25.7 (9.0) 30.9 (9.6) 28.1 (6.7) 39.1 (5.9)
   Crude OR (95% CI) 1 0.86 (0.64−1.16) 0.63 (0.36−1.13) 0.67 (0.26−1.67) 0.85 (0.35−2.07) 0.75 (0.39−1.43) 1.23 (0.75−2.00)
   Adjusted ORb (95% CI) 1 0.92 (0.66−1.27) 0.64 (0.37−1.11) 0.52 (0.18−1.51) 1.04 (0.40−2.74) 1.03 (0.53−1.98) 1.19 (0.69−2.06)
Metabolic Syndromea       
   Estimated proportion % (SE) 33.5 (0.6) 28.5 (3.3) 13.5 (4.5) 43.3 (13.4) 43.9 (9.5) 26.8 (6.4) 28.1 (4.9)
   Crude OR (95% CI) 1 0.79 (0.58−1.09) 0.34 (0.16−0.72) 1.51 (0.52−4.41) 1.59 (0.74−3.40) 0.73 (0.38−1.38) 0.72 (0.45−1.16)
   Adjusted ORb (95% CI) 1 0.80 (0.56−1.14) 0.42 (0.20−0.86) 1.60 (0.57−4.54) 1.40 (0.62−3.18) 0.75 (0.33−1.71) 0.67 (0.37−1.22)
SE, standard error; OR, odds ratio; CI, confidence interval; HDL, high density lipoprotein; aClinical diagnosis of metabolic syndrome was 
made on the basis of meeting ≥3 of the following criteria: (1) abdominal obesity, waist circumference > 90 cm (males) or 80 cm (females); (2) 
triglycerides ≥ 150 mg/dL; (3) HDL cholesterol < 40 mg/dL (males) or 50 mg/dL (females); (4) systolic blood pressure ≥ 130 mm Hg, diastolic 
blood pressure ≥ 85 mm Hg; (5) fasting glucose ≥ 100 mg/dL; or current medication for treatment of any of the above conditions such as 
statins, anti−hypertensive drugs, and anti−diabetic medications; bAdjusted by gender, age, education, income, residential area, BMI, smoking, 
alcohol drinking, physical activity, depression, and suicidal idea      
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compared to non-cancer controls (aOR 0.89, 95% CI 
0.59−1.34).
Factors associated with metabolic syndrome among 
cancer survivors
The factors shown to be associated with metabolic 
syndrome by univariate analysis (Model 1) were age 
group, BMI, and cancer type (Table 3). All variables 
used in the univariate analysis were included in the 
multivariate analysis (Model 2). Model 2 controlled 
for socio-demographic factors, psychological factors, 
behavioral factors, and oncological factors. The risk for 
metabolic syndrome among cancer survivors was related 
with age group, and BMI after adjusting co-variates. 
Cancer survivors aged ≥60 years had higher risk for 
metabolic syndrome (aOR 4.83, 95% CI 1.94−12.03) 
compared with those in the reference category (40−59 
years). Cancer survivors with BMI level 23−25 had 
higher odds ratio for metabolic syndrome (aOR 6.71, 
95% CI 2.90−15.57) than group with BMI <23. Highest 
odds ratio for metabolic syndrome was found in cancer 
survivors who had BMI ≥25 (aOR 12.23, 95% CI 
5.20−28.77). Gastric cancer survivors were less likely 
to have metabolic syndrome than other cancer types 
excluding stomach cancer (aOR 0.56, 95% CI 0.24−1.30). 
However, this association was not statistically significant.
 
Discussion
In this study, cancer survivors had similar or even 
better metabolic syndrome component compared to the 
non-cancer controls. Among Korean cancer survivors 
aged ≥40years, 28.5% had metabolic syndrome. Previous 
studies from western countries have demonstrated that 
the results varied according to cancer types. Cancer 
survivors from hematologic malignancies showed higher 
odds ratios for metabolic syndrome (Kourti et al., 2005; 
Follin et al., 2006; Gurney et al., 2006; Trimis et al., 
2007). However, inconsistent results were observed in 
cancer survivors with solid tumors (Nuver et al., 2005; 
Braga-Basaria et al., 2006; Haugnes et al., 2007). Based 
on the Third National Health and Nutrition Examination, 
U.S. population-based surveys, the prevalence of 
metabolic syndrome was higher among cancer survivors 
than non-cancer controls (Ness et al., 2005). In Korea, 
the distribution of prevalent cancer type is different from 
Western countries. Furthermore, there are few studies 
about the associations between the gastric cancer and 
metabolic syndrome, which is one of the most common 
cancers in Korea. 
Gastric cancer patients had lower risk for metabolic 
syndrome compared to the general population. 
Gastrectomy is the gold standard for curative treatment 
modality performed on gastric cancer patients (Brennan 
and Karpeh, 1996). Previous studies have shown that 
poor nutritional status was observed in patients who 
had undergone gastrectomy (Bae et al., 1998; Carey et 
al., 2011). After the operation, severe fat malnutrition 
and vitamin deficiency were found (Bae et al., 1998). 
Major upper gastrointestinal surgery affects permanent 
alterations to the gastrointestinal tract, and therefore 
results in weight loss, body change, and malabsorption 
(Carey et al., 2011). Moreover, bariatric surgery can 
provide sustained weight loss and reduced obesity-related 
mortality by reducing gastric size (Ashrafian et al., 2011). 
Table 3. Factors in Univariate and Multivariate 
Analysis Models     
 
       Model 1            Model 2  
Variables             Univariate     95%     Multivariate     95%  
                                 OR           CI        OR               CI
Socio−demographic factors    
  Sex     
    Male 1   1 
    Female 1.55 (0.76−3.18)  1.42 (0.56−3.58)
  Age      
    40−59 1   1 
     ≥60 2.11 (1.08−4.15)  4.83 (1.94−12.03)
  Education level      
    ≤Elementary 1   1
    Middle/high 0.57 (0.29−1.12)  0.69 (0.29−1.68)
    ≥College 0.29 (0.06−1.54)  0.4 (0.91−1.73)
  Monthly income ($)     
    < 573 1   1 
    573−1,332 1.04 (0.52−2.10)  1.86 (0.77−4.45)
     ≥ 1,332 0.59 (0.26−1.33)  1.26 (0.45−3.45)
  Residential area      
    Urban 1   1 
    Rural 0.8 (0.43−1.47)  0.82 (0.42−1.61)
Behavioral factors     
  BMI 
     <23 1   1 
     ≥23 & <25 6.08 (2.56−14.46)  6.71 (2.90−15.57)
     ≥25 9.34 (4.18−20.91)  12.2 (5.20−28.77)
  Smoking      
    Past smoker 1   1 
    Current smoker 1.67 (0.50−5.80)  1.47 (0.42−5.15)
  Alcohol      
    Non 1   1 
    Heavy drinkinga 1.65 (0.39−6.94)  1.27 (0.29−5.61)
  Physical activity     
     Inadequate 1   1 
     Adequateb 0.71 (0.36−1.38)  1.04 (0.49−2.19)
Psychological factors    
  Self−reported depression     
    No 1   1 
    Yes 1.09 (0.38−3.84)  0.71 (0.16−3.42)
  Suicidal idea within 1 year    
     No  1   1 
     Yes 1.56 (0.79−3.05)  0.89 (0.34−2.31)
Oncological factors     
  Type    
     Others  1   1 
     Gastric cancer 0.34 (0.18−0.64)  0.56 (0.24−1.30)
  Duration since diagnosis    
     <5 1   1 
     ≥5 & <10 1.06 (0.49−2.29)  1.05 (0.45−2.46)
     ≥10 1.32 (0.62−2.78)  1.05 (0.45−2.48)
OR, odds ratio; CI, confidence interval; aHeavy drinking 
defined as self−reported more than 5 drinks on a single 
occasion, or daily drinking of more than 1 drink per day; b 
Adequate physical activity defined as doing 30 minutes of 
moderate−intensity physical activity on 5 or more days of the 
week or 20 minutes of vigorous−intensity physical activity on 
3 or more days of the week
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Although there are few studies about the association 
between gastric cancer and metabolic syndrome, 
we could explain the lower prevalence of metabolic 
syndrome among Korean cancer survivors through the 
relatively high proportions of gastric cancer patients in 
Korea. Despite failing to show statistical significance, 
breast cancer and colon cancer survivors had higher aOR 
for metabolic syndrome than non-cancer controls. There 
can be an increasing prevalence for metabolic syndrome 
in the near future due to the increasing trend of breast and 
colon cancer and the decreasing trend of gastric cancer 
in Korea (Jung et al., 2011).
General risk factors for metabolic syndrome are 
female, old age, high BMI, current smoking status, 
heavy alcohol consumption, inadequate physical activity 
and low socio-economic level (Park et al., 2004; Erem 
et al., 2008; Mohamud et al., 2011; Rodrigues et al., 
2013). In our study, only 2 risk factors (age and BMI) 
among many variables showed a significant association 
with metabolic syndrome in cancer survivors. Age is 
well accepted to be one of the strongest predictor of 
metabolic syndrome in the general population (Riediger 
and Clara, 2011). This finding is consistent with those 
of other studies carried out in Korea as well as world-
wide (Ford et al., 2002; Park et al., 2004; Erem et al., 
2008; Mohamud et al., 2011; Rodrigues et al., 2013 ). 
This association is due to the inevitable physiological 
processes of aging, such as declining basal metabolic 
rate, changes in body composition, and unhealthy 
lifestyle (Bechtold et al., 2006). While muscle mass 
decreases up to 40% from 20 to 70 years of age (Villareal 
et al., 2005), fat mass increases with the predominance 
of abdominal fat accumulation (Visser et al., 1998), 
and these aging-related changes lead to increasing 
intra-abdominal fat, specifically central obesity, which 
is associated with cardiovascular disease risk factors 
(Grinker et al., 1995; Bo et al., 2009). Management of 
metabolic syndrome in the elderly is difficult because 
co-management of multiple co-morbid conditions is often 
required (Bechtold et al., 2006). Especially for cancer 
survivors, a higher proportion of non-cancer mortalities 
was observed in the elderly than the younger age-group 
(Shin et al., 2010a). Moreover, cancer survivors were 
less likely to have an appropriate medication adherence, 
and the proportion of adherence was lower in the old age 
group than in the young age group (Shin et al., 2010b). 
Considering the previously mentioned aspects, treatment 
of metabolic syndrome among elderly cancer survivors 
is one of the most challenging issues. Therefore, primary 
prevention and early intervention should be required to 
manage the metabolic syndrome among cancer survivors, 
especially for the elderly.  
We observed that aOR increased with higher BMI 
when adjusting for other variables, and that BMI was 
the most sensitive marker for the metabolic syndrome. 
This finding is consistent with previous studies from 
general population in Korea and the United States (Park 
et al., 2003; Park et al., 2004). The pathophysiology 
of the metabolic syndrome is largely attributable to 
insulin resistance. Overweight, obesity, and especially a 
central pattern of fat accumulation are related to insulin 
resistance (Lechleitner, 2008). Obesity is associated with 
cancer recurrence and mortality in some cancer types 
such as breast, colon, and prostate cancer (Meyerhardt 
et al., 2003; Amling et al., 2004; Whiteman et al., 
2005). Obese survivors in cancers with high long-term 
survival, such as breast, colon, and prostate cancers, 
may have greater chance to be exposed to the obesity-
related co-morbidities and mortalities than patients 
with aggressive cancers (Park et al., 2006). Moreover, 
treatment-related weight gain is often observed in breast 
and prostate cancer patients due to hormonal therapy or 
reduced physical activity (Tayek et al., 1990; Chlebowski 
et al., 2002). Efforts to control weight may be a key 
strategy to reduce mortality from cancer as well as to 
prevent metabolic syndrome. In breast cancer survivors, 
significant reductions in fasting serum insulins and leptin 
as well as significant improvement in quality of life 
were observed with weight control intervention (Befort 
et al., 2012).  
As the number of long-term cancer survivors is 
growing, the evaluation and management of their 
health-related problems have become an important 
issue. Cardiovascular disease is the most common 
cause of non-cancer mortality in cancer survivors, and 
metabolic syndrome represents the link to the increased 
cardiovascular disease (Brown et al., 1993; Shin et al., 
2010a). Among cancer survivors, old age and high BMI 
are identified as risk factors for metabolic syndrome. It 
is important for the healthcare provider to assess and 
screen the metabolic syndrome of cancer survivors who 
are elderly and obese. While age and cancer type are non-
modifiable factors, BMI can be modifiable with efforts 
to control weight. Thus, weight control intervention 
program should be suggested for long-term cancer 
survivors to prevent metabolic syndrome.
Several limitations should be considered in our 
studies. First, we could not document causal association 
between factors and metabolic syndrome because of the 
cross-sectional nature of our study design(Forootan et 
al., 2012). Because obesity is associated with increased 
risk for some cancer types such as breast and endometrial 
cancer, the causal relationship between obesity and 
cancer is obscure(Ronco et al., 2012). In addition, 
Preexisting metabolic syndrome before diagnosis and 
treatment among cancer survivors could not be identified 
due to lack of available data. Second, several important 
information could not be collected from survey. We 
could not know treatment modalities of each patient 
from survey. Changes in endocrine and metabolic 
functions varied according to treatment modality such 
as systemic cancer therapy (hormone therapy and 
chemotherapy), and local treatments (radiation and 
surgery). Because several common cancer types such as 
liver, lung, thyroid and prostate cancer were included in 
other cancer groups, we could not estimate the precise 
association with metabolic syndrome in those cancer 
survivors. Therefore, information about various cancer 
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